3 New Strong Buy Ratings from Top-Rated Analysts: 10/28/2026
Here’s the latest from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Target (TGT): Holiday season and retail media fuel the comeback
- Park Ohio Holdings (PKOH): Record revenue, raised guidance, 38% upside target
- Corcept Therapeutics (CORT): Two top-rated analysts see 90%+ upside ahead
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
10 AI Infrastructure Stocks to Watch
Free report reveals 10 publicly traded companies positioned across key layers of the AI ecosystem, from chip fabrication and custom silicon to data storage, connectivity, and cooling solutions. Plus insight into the major risks that could impact the AI infrastructure trade, including valuation concerns, industry cycles, geopolitical challenges, and execution risks.
1. Target (NYSE: TGT)
With the holiday shopping season approaching, Target is positioning itself to capture consumer spending through strategic merchandising initiatives and its growing Roundel retail media business.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $148.80 — get current quote
Max 1-year forecast: $190.00
Why we're watching:
- TGT has strong coverage among the analysts we track, with 6 Strong Buy, 4 Buy, and 12 Hold recommendations. See all recommendations here
- For example, UBS researcher Michael Lasser (a top 4% rated analyst) recently maintained his Strong Buy rating with a price target greater than 20% upside potential from current levels.
- It’s also our Stock of the Week … Our Editor-in-Chief calls TGT his “favorite stock of the holiday season,” praising the turnaround story in progress and pointing to ample upside ahead. See his commentary here
- Industry ranking context: TGT is currently the #1 highest-rated stock in the Discount Store industry, which has an Industry Rating of A.
- Zen Ratings highlights: TGT earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks in this topmost tier have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: TGT demonstrates well-rounded strength with solid Bs across Financials, Growth, Momentum, Value, and Sentiment positioning it as a balanced retailer with appeal across multiple investment strategies. See all 7 Component Grades here
2. Park Ohio Holdings (NASDAQ: PKOH)
Following a strong Q2 2026 earnings report that delivered record revenue and improved operating margins, this industrial manufacturing company raised guidance and is building momentum heading into 2027.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $42.86 — get current quote
Max 1-year forecast: $59.00
Why we're watching:
- PKOH has limited, but strongly bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, KeyBanc researcher Steve Barger (a top 4% rated analyst) recently maintained his Strong Buy recommendation with a price target pointing to roughly 40% upside potential from current levels. Barger described the Q2 results as "strong" and highlighted management's raised guidance, noting that Park Ohio delivered record quarterly revenue and its highest operating margin in six quarters.
- Industry ranking context: PKOH is currently the #1 highest-rated stock in the Specialty Industrial Machinery industry, which has an Industry Rating of B.
- Zen Ratings highlights: PKOH earns an overall A rating, which translates to a Strong Buy recommendation. This top-tier rating reflects the company's passage of a rigorous 115-factor fundamental review, placing it among the elite stocks tracked.
- Component Grades: PKOH excels with As for both Growth and Safety, reflecting record quarterly revenue alongside consistent operational performance, while maintaining solid Bs for Value, Momentum, and Sentiment, a combination that supports continued appreciation potential. See all 7 Component Grades here
3. Corcept Therapeutics (NASDAQ: CORT)
This is a pharmaceutical firm dedicated to treatments for severe metabolic and psychiatric disorders. With upcoming clinical trial results and recent FDA approvals, the company is positioned for robust pipeline-driven growth.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $85.95 — get current quote
Max 1-year forecast: $165.00
Why we're watching:
- CORT has solid coverage among the analysts we track, with 3 Strong Buy, 1 Buy, and 1 Sell recommendations. See all recommendations here
- For example, HC Wainwright & Co. researcher Swayampakula Ramakanth (a top 3% rated analyst) recently reiterated his Buy with a price target suggesting the stock could still see greater than 90% upside in the coming year.
- He’s not alone. Piper Sandler researcher David Amsellem (a top 4% rated analyst) reiterated his Strong Buy with a similar price target, expecting robust growth driven by pipeline advancements.
- Industry ranking context: CORT is currently the #9 highest-rated stocks in the Biotech industry.
- Zen Ratings highlights: CORT earns an overall A rating, equal to a Strong Buy recommendation. Stocks with this rating represent the elite top 5% of all 4,600+ stocks tracked based on a rigorous 115-factor fundamental review.
- Component Grades: CORT excels with an A for Growth, reflecting the company's strong revenue expansion and pipeline potential, while maintaining solid Bs for Financials, Momentum, and Value, a combination that underscores its balanced risk-reward profile. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.